A retrospective study of advanced progressive sarcoma treated by Anlotinib
LONG Zuo-yao
LU Ya-jie
LI Ming-hui
CHEN Guo-jing
WANG Feng-wei
LIU Dong
HUANG Hai
ZHANG Hong-mei
WANG Zhen
Abstract：Objective To evaluate the efficacy of advanced progressive sarcoma treated by Anlotinib. Methods From June to November 2018, all advanced progressive sarcoma patients in our hospital were included. After evaluation of status, patients received Anlotinib 12 mg once daily, 2-week on/1-week off, in a 3-week cycle. Patients would have surgery first if they had surgical indications. Outcomes were assessed by tumor volume and imagelogy diversity. Toxicity was recorded using CTCAE version 4.03. Results Seventeen patients were enrolled. Ten of them were male, and the others were female, with a mean age of (41.7 ± 22.4) years. Pathological findings: 4 osteosarcoma, 3 chondrosarcoma, 3 undifferentiated polymorphous sarcoma, 2 epithelioid sarcoma, 2 leiomyosarcoma, 1 alveolar soft part sarcoma, 1 intraabdominal desmoplastic small round cell tumor, 1 fibrosarcoma. 2 patients had PR (11.76％), 11 patients had SD (64.70％), 4 patients had PD (23.54％). The ORR was 11.76％, and DCR was 76.46％. The most common adverse events were anorexia (35.29％), fatigue (23.53％), hypertension (11.76％). Conclusions Anlotinib shows antitumor activity in advanced progressive sarcoma entities with a manageable tolerability, which could be a new treatment approach.
Keywords：AnlotinibSarcomaEfficacySafety
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 3-9 )